Virtual Tumour platform - AACR Annual Meeting 2015

RNS Number : 8910K

Physiomics PLC

22 April 2015

 



Physiomics plc

("Physiomics") or ("the Company")

Physiomics to present new developments of the Virtual Tumour platform in immunotherapy at Annual Meeting for American Association for Cancer Research ("AACR")

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015.  Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy.

Our Virtual Tumour platform has been extended to model immunomodulatory agents, currently a significant focus of cancer research. This extension captures the mechanisms by which immune checkpoint inhibitors activate the antitumor immune response and synergizes with other anticancer therapies. In this poster, through a preclinical case study we demonstrate that the extended Virtual Tumour can be applied to model the efficacy of such immune-checkpoint blockers, both alone and in combination with irradiation. The model predictions were validated against published experimental data, and found to accurately reflect the synergy of the combination treatment.

The abstract ("Modeling synergistic anti-PD-1 immunotherapy combinations with virtual tumor", No 4866) will be presented in the "Methods and Tools in Computational Cancer Biology" poster session, scheduled 8:00 AM-12:00 PM, 22 April 2015.

More information about the conference may be found at:

http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=25&DetailItemID=156#.VTTTdcJ0ycw

Dr Mark Chadwick, CEO of Physiomics, commented:

"Our enhanced Virtual Tumour capability represents the first step towards a ground-breaking tool for optimizing dosing and scheduling of immunotherapy, which is set to revolutionize cancer therapy in the near future, especially for patients with resistant disease. Based on this successful preclinical result, we are now looking into translating these results into the Clinical version of the Virtual Tumour"

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRALLFEVSSILFIE